These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 21702914)

  • 41. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging.
    Weber WA; Ott K; Becker K; Dittler HJ; Helmberger H; Avril NE; Meisetschläger G; Busch R; Siewert JR; Schwaiger M; Fink U
    J Clin Oncol; 2001 Jun; 19(12):3058-65. PubMed ID: 11408502
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [18F]-fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemotherapy in gastric cancer.
    Vallböhmer D; Hölscher AH; Schneider PM; Schmidt M; Dietlein M; Bollschweiler E; Baldus S; Alakus H; Brabender J; Metzger R; Mönig SP
    J Surg Oncol; 2010 Aug; 102(2):135-40. PubMed ID: 20648583
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study.
    Ueda S; Tsuda H; Saeki T; Omata J; Osaki A; Shigekawa T; Ishida J; Tamura K; Abe Y; Moriya T; Yamamoto J
    Breast Cancer; 2011 Oct; 18(4):299-308. PubMed ID: 20617404
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The new credo: induction chemotherapy in locally advanced gastric cancer: consequences for surgical strategies.
    Ott K; Lordick F; Herrmann K; Krause BJ; Schuhmacher C; Siewert JR
    Gastric Cancer; 2008; 11(1):1-9. PubMed ID: 18373171
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neoadjuvant radio-chemotherapy of adenocarcinoma of the oesophagogastric junction.
    Samel S; Hofheinz R; Hundt A; Sturm J; Knoll MR; Wenz F; Queisser W; Post S
    Onkologie; 2001 Jun; 24(3):278-82. PubMed ID: 11455222
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
    Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
    [No Abstract]   [Full Text] [Related]  

  • 47. Spatial-temporal [¹⁸F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy.
    Tan S; Kligerman S; Chen W; Lu M; Kim G; Feigenberg S; D'Souza WD; Suntharalingam M; Lu W
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1375-82. PubMed ID: 23219566
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The value of 18F-FDG-PET testing in the management of esophageal and gastroesophageal junction adenocarcinoma - review.
    Zemanová M; Obermannová R; Haruštiak T
    Klin Onkol; 2021; 34(2):113-119. PubMed ID: 33906359
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PET-directed combined modality therapy for gastroesophageal junction cancer: Results of the multicentre prospective MEMORI trial of the German Cancer Consortium (DKTK).
    Lorenzen S; Quante M; Rauscher I; Slotta-Huspenina J; Weichert W; Feith M; Friess H; Combs SE; Weber WA; Haller B; Angele M; Albertsmeier M; Blankenstein C; Kasper S; Schmid RM; Bassermann F; Schwaiger M; Liffers ST; Siveke JT
    Eur J Cancer; 2022 Nov; 175():99-106. PubMed ID: 36099671
    [TBL] [Abstract][Full Text] [Related]  

  • 50.
    Xi M; Liao Z; Hofstetter WL; Komaki R; Ho L; Lin SH
    J Nucl Med; 2017 Nov; 58(11):1756-1763. PubMed ID: 28522744
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Positron emission tomography and pathological evidence of response to neoadjuvant therapy in adenocarcinoma of the esophagus.
    Smithers BM; Couper GC; Thomas JM; Wong D; Gotley DC; Martin I; Harvey JA; Thomson DB; Walpole ET; Watts N; Burmeister BH
    Dis Esophagus; 2008; 21(2):151-8. PubMed ID: 18269651
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer.
    Levine EA; Farmer MR; Clark P; Mishra G; Ho C; Geisinger KR; Melin SA; Lovato J; Oaks T; Blackstock AW
    Ann Surg; 2006 Apr; 243(4):472-8. PubMed ID: 16552197
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Is the standardized uptake value of FDG-PET/CT predictive of pathological complete response in locally advanced rectal cancer treated with capecitabine-based neoadjuvant chemoradiation?
    Bampo C; Alessi A; Fantini S; Bertarelli G; de Braud F; Bombardieri E; Valvo F; Crippa F; Di Bartolomeo M; Mariani L; Milione M; Biondani P; Avuzzi B; Chiruzzi C; Pietrantonio F
    Oncology; 2013; 84(4):191-9. PubMed ID: 23328390
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus.
    Malik V; Lucey JA; Duffy GJ; Wilson L; McNamara L; Keogan M; Gillham C; Reynolds JV
    J Nucl Med; 2010 Dec; 51(12):1863-9. PubMed ID: 21078796
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer.
    Dose-Schwarz J; Tiling R; Avril-Sassen S; Mahner S; Lebeau A; Weber C; Schwaiger M; Jänicke F; Untch M; Avril N
    Br J Cancer; 2010 Jan; 102(1):35-41. PubMed ID: 19920815
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.
    Groheux D; Hindié E; Giacchetti S; Hamy AS; Berger F; Merlet P; de Roquancourt A; de Cremoux P; Marty M; Hatt M; Espié M
    Eur J Cancer; 2014 Jul; 50(11):1864-71. PubMed ID: 24841218
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction.
    Ott K; Weber WA; Lordick F; Becker K; Busch R; Herrmann K; Wieder H; Fink U; Schwaiger M; Siewert JR
    J Clin Oncol; 2006 Oct; 24(29):4692-8. PubMed ID: 16966684
    [TBL] [Abstract][Full Text] [Related]  

  • 58.
    Lehmann K; Eshmuminov D; Bauerfeind P; Gubler C; Veit-Haibach P; Weber A; Abdul-Rahman H; Fischer M; Reiner C; Schneider PM
    Eur J Surg Oncol; 2017 Jan; 43(1):196-202. PubMed ID: 27692533
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tumor response to neoadjuvant chemotherapy in patients with esophageal cancer assessed with CT and FDG-PET/CT - RECIST 1.1 vs. PERCIST 1.0.
    Odawara S; Kitajima K; Katsuura T; Kurahashi Y; Shinohara H; Yamakado K
    Eur J Radiol; 2018 Apr; 101():65-71. PubMed ID: 29571803
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Monitoring of neoadjuvant chemotherapy using multiparametric, ²³Na sodium MR, and multimodality (PET/CT/MRI) imaging in locally advanced breast cancer.
    Jacobs MA; Ouwerkerk R; Wolff AC; Gabrielson E; Warzecha H; Jeter S; Bluemke DA; Wahl R; Stearns V
    Breast Cancer Res Treat; 2011 Jul; 128(1):119-26. PubMed ID: 21455671
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.